<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Oral leukoplakia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Oral leukoplakia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Oral leukoplakia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Giovanni Lodi, DDS, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert P Dellavalle, MD, PhD, MSPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel G Deschler, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3441469379">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral leukoplakia is an oral potentially malignant disorder that presents as white patches of the oral mucosa. According to the World Health Organization, the term "leukoplakia" should be reserved for "white plaques of questionable risk, having excluded other known diseases or disorders that carry no increased risk for cancer" [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         A separate disorder that is
         <strong>
          not
         </strong>
         premalignant is oral hairy leukoplakia  (
         <a class="graphic graphic_picture graphicRef72106" href="/z/d/graphic/72106.html" rel="external">
          picture 1
         </a>
         ), an Epstein-Barr virus-induced lesion that occurs almost entirely in patients infected with human immunodeficiency virus (HIV). Oral lichen planus is also reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">
          "Clinical manifestations and treatment of Epstein-Barr virus infection", section on 'Oral hairy leukoplakia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15285.html" rel="external">
          "Oral lichen planus: Pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86851.html" rel="external">
          "Oral lichen planus: Management and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2472161396">
         <span class="h1">
          EPIDEMIOLOGY AND RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral leukoplakia is not a rare condition. A systematic review pooling data from studies with at least 1000 individuals estimated that the prevalence in the general population is between 0.3 and 4.1 percent, with high heterogeneity among continents and the highest prevalence rates recorded in Asia and Oceania [
         <a href="#rid2">
          2,3
         </a>
         ]. Risk factors for oral leukoplakia are similar to those for squamous cell carcinoma (SCC), including tobacco use (smoked and smokeless) and alcohol drinking [
         <a href="#rid4">
          4
         </a>
         ]. In addition, leukoplakia has been shown to be associated with human papillomavirus (HPV) infection [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3557337650">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of oral leukoplakia is largely unknown. It is considered an intermediate stage in oral carcinogenesis, driven by multiple somatic genetic mutations affecting keratinocyte growth, survival, and cycle control. These result in histopathologic (hyperkeratosis, hyperplasia, dysplasia) and clinical (change of color, thickness, and texture) modifications.
        </p>
        <p class="headingAnchor" id="H2880036258">
         <span class="h2">
          Genetic and molecular alterations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Copy number alterations that originate from gains, amplifications, deletions, and insertions of deoxyribonucleic acid (DNA) sequences involving known oncogenic drivers (eg,
         <em>
          CDKN2A
         </em>
         ,
         <em>
          CCND1
         </em>
         ,
         <em>
          EGFR
         </em>
         , and
         <em>
          MYC
         </em>
         ) have been found with high frequency in oral leukoplakia [
         <a href="#rid6">
          6
         </a>
         ]. Other common features of oral leukoplakia include DNA ploidy abnormalities; positive telomerase activity; loss of heterozygosity (particularly on 3p, 4q, 9p, and 17p); and gene mutations, the most frequent being those affecting
         <em>
          TP53
         </em>
         , followed by
         <em>
          NOTCH1
         </em>
         ,
         <em>
          FAT1
         </em>
         ,
         <em>
          CDKN2A
         </em>
         ,
         <em>
          KMT2C
         </em>
         , and
         <em>
          PIK3CA
         </em>
         [
         <a href="#rid7">
          7-9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H274225252">
         <span class="h2">
          Immune profile
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increased expression of human leukocyte antigen (HLA) G/E, interleukin (IL) 10, transforming growth factor (TGF)-beta 2/3, programmed cell death protein 1 (PD-1), and programmed death ligand 1 (PD-L1) has been demonstrated in oral leukoplakia, irrespective of the degree of epithelial dysplasia [
         <a href="#rid10">
          10,11
         </a>
         ]. Increased density of CD8
         <sup>
          +
         </sup>
         T cells, cytotoxic T cells, and T regulatory cells, as well as overexpression of PD-L1, has been demonstrated in proliferative verrucous leukoplakia (PVL) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1863772525">
         <span class="h2">
          Oral microbiota
         </span>
         <span class="headingEndMark">
          —
         </span>
         It has been hypothesized that dysbiosis might play a role in the development of leukoplakia and oral potentially malignant disorders. A few studies investigating the microbiome associated with oral leukoplakia showed that
         <em>
          Haemophilus
         </em>
         ,
         <em>
          Fusobacterium
         </em>
         ,
         <em>
          Leptotrichia
         </em>
         , and
         <em>
          Campylobacter
         </em>
         were found to be significantly more abundant in oral leukoplakia compared with nonaffected tissues; the genera found were different from those associated with oral squamous cell carcinoma (SCC) [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3019489172">
         <span class="h2">
          Biomarkers and risk of oral cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         The molecular mechanisms underlying the progression from dysplasia to invasive cancer involve the accumulation of genetic alterations in tumor suppressor genes and oncogenes [
         <a href="#rid14">
          14
         </a>
         ]. Genetic abnormalities that have been found in both oral SCC and nondysplastic leukoplakia include copy number alterations, DNA hypermethylation, increased expressions of microribonucleic acids (microRNAs), and altered expression of p53 and p16INK4a [
         <a href="#rid15">
          15-18
         </a>
         ]. Despite the existing extensive literature on the topic, there is insufficient evidence to support the clinical use of any marker to predict oral cancer development in patients affected by oral leukoplakia, although DNA ploidy and expression of podoplanin might be the most promising among the biomarkers investigated [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H68554693">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
        </p>
        <p class="headingAnchor" id="H2927296611">
         <span class="h2">
          Clinical subtypes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Leukoplakia presents as white patches of the oral mucosa that cannot be wiped off with a gauze. It is clinically classified into two forms, homogeneous and nonhomogeneous leukoplakia, with the latter carrying a higher risk of oral cancer compared with the homogeneous form [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Homogeneous leukoplakia
         </strong>
         – Homogeneous leukoplakia typically presents as a uniformly white plaque with regular texture and well-defined margins  (
         <a class="graphic graphic_picture graphicRef81049 graphicRef72711" href="/z/d/graphic/81049.html" rel="external">
          picture 2A-B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonhomogeneous leukoplakia
         </strong>
         – Nonhomogeneous leukoplakia presents with speckled (red and white, but predominantly white) lesions; erythroleukoplakia (red and white lesions)  (
         <a class="graphic graphic_picture graphicRef60939" href="/z/d/graphic/60939.html" rel="external">
          picture 3
         </a>
         ); or granular, nodular, or verrucous, white lesions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Proliferative verrucous leukoplakia
         </strong>
         – Proliferative verrucous leukoplakia (PVL) is a rare, multifocal, aggressive form of nonhomogeneous leukoplakia associated with an extremely high risk of malignant transformation  (
         <a class="graphic graphic_picture graphicRef95480" href="/z/d/graphic/95480.html" rel="external">
          picture 4
         </a>
         ). (See
         <a class="local">
          'Proliferative verrucous leukoplakia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3497366454">
         <span class="h2">
          Clinical features associated with increased risk of oral cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonhomogeneous clinical subtype, large size (&gt;4 cm in largest diameter), extension over more than one anatomical site, localization (lateral border of the tongue and floor of the mouth), and especially the presence of dysplasia on histologic examination are the most important predictors of cancer [
         <a href="#rid21">
          21-24
         </a>
         ]. The extent or grade of dysplasia is widely used to assess risk of transformation, despite the high variability among pathologists in the identification and grading of epithelial dysplasia [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2407327608">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H2039620579">
         <span class="h2">
          Clinical suspicion
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of leukoplakia is suspected in patients presenting with a white lesion of the oral mucosa that cannot be wiped off with a gauze; that does not appear of traumatic, frictional, or otherwise reactive nature; and/or persists after eliminating potential etiologic factors, such as mechanical friction, for a six-week period [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5572.html" rel="external">
          "Oral lesions", section on 'White and red oral lesions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3805097752">
         <span class="h2">
          Biopsy and histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The definitive diagnosis requires a biopsy for histopathologic examination to assess the presence and grade of dysplasia and to exclude other oral disorders that present with white lesions  (
         <a class="graphic graphic_algorithm graphicRef118579" href="/z/d/graphic/118579.html" rel="external">
          algorithm 1
         </a>
         ). Sampling multiple areas of the lesion is recommended.
        </p>
        <p>
         Histopathologic features of leukoplakia may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Benign hyperkeratosis (not reactive)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Parakeratosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atrophy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inflammation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperplasia, including atypical verrucous hyperplasia (not reactive), without dysplasia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Various grades of dysplasia (mild, moderate, severe, or alternatively defined as low or high grade)
        </p>
        <p>
        </p>
        <p>
         Sometimes, areas of carcinoma in situ or even invasive carcinoma can be found in contiguity or within leukoplakia lesions [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
         Epithelial dysplasia, oral squamous cell carcinoma (SCC) in situ, or invasive SCC have been reported with variable frequency across studies, ranging from approximately 10 to up to 60 percent of lesions. It should be noted that the diagnosis of dysplasia may be difficult, and there is considerable variability among pathologists in detection and grading of epithelial dysplasia [
         <a href="#rid25">
          25,29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3375.html" rel="external">
          "Pathology of head and neck neoplasms", section on 'Squamous dysplasia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1311750000">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis includes a wide range of conditions presenting as white patches or plaques, including frictional keratosis, lichen planus, discoid lupus erythematosus, submucous fibrosis, candidiasis, and hairy leukoplakia  (
         <a class="graphic graphic_algorithm graphicRef118579" href="/z/d/graphic/118579.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5572.html" rel="external">
          "Oral lesions", section on 'White and red oral lesions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4225773433">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to the management of patients presenting with leukoplakia is discussed below. (See
         <a class="local">
          'Our approach'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2545242438">
         <span class="h2">
          Choice of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary aim of leukoplakia treatment is to prevent or decrease the risk of oral squamous cell carcinoma (SCC) [
         <a href="#rid30">
          30
         </a>
         ]. However, there is limited evidence from high-quality studies to guide clinicians in the choice of treatment, and there is no consensus among experts on the management approach [
         <a href="#rid30">
          30,31
         </a>
         ]. For this reason, patients must undergo a surveillance program at regular intervals, depending on risk stratification. In clinical practice, the choice of treatment is made based upon lesion size and type (eg, homogeneous versus nonhomogeneous), presence and grade of histopathologic dysplasia, clinical experience, and the patient's characteristics (age and comorbidities) and preferences [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Treatment options include surgery, destructive therapies (eg, laser ablation, cryosurgery), medical therapies (eg, retinoids,
         <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">
          vitamin A
         </a>
         , carotenoids, nonsteroidal anti-inflammatory drugs [NSAIDs], immunomodulators [
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         ]), and watchful waiting with close clinical and histologic follow-up. The main drawback of destructive treatments is that they do not allow histopathologic examination of the entire lesion, which may present pathologic features (high-grade dysplasia, occult cancer foci) that were not present in the diagnostic biopsy specimens [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Our approach to the management of patients with oral leukoplakia is outlined below. (See
         <a class="local">
          'Our approach'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2287302161">
         <span class="h2">
          Surgical therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical techniques for removal of oral leukoplakia include conventional cold scalpel excision and laser excision using lasers of different wavelengths, such as carbon dioxide (CO
         <sub>
          2
         </sub>
         ), neodymium-doped yttrium aluminum garnet (Nd:YAG), erbium-doped yttrium aluminum garnet (Er:YAG), and diode. Limited data from observational studies and retrospective case series indicate recurrence rates of approximately 15 to 30 percent following surgical excision, irrespective of the technique used, and development of oral SCC in 4 to 20 percent [
         <a href="#rid30">
          30,33-38
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical excision
         </strong>
         – Although surgery is considered first-choice treatment by many relevant specialists [
         <a href="#rid30">
          30,33
         </a>
         ], there is only one randomized trial evaluating its efficacy in the prevention of oral cancer. The trial showed that surgical excision of nondysplastic lesions provided no benefits when compared with standard care (follow-up visits every six months and repeated biopsies as needed) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laser excision
         </strong>
         – Laser excision might offer some advantages, such as good hemostasis during the procedure and more rapid wound healing, particularly in case of large lesions. However, this technique may cause tissue alterations that may jeopardize histopathologic analysis. Reported recurrence rates following CO
         <sub>
          2
         </sub>
         laser excision range from 10 to over 50 percent [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Photodynamic therapy
         </strong>
         – Photodynamic therapy employing different photosensitizers (
         <a class="drug drug_general" data-topicid="9199" href="/z/d/drug information/9199.html" rel="external">
          aminolevulinic acid
         </a>
         , photofrin,
         <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">
          methylene blue
         </a>
         , and chlorin e6) and different parameters (wavelength, duration of irradiation, and power density) for the treatment of oral leukoplakia has been described in several studies. However, none of the studies included in a systematic review used oral cancer onset as an outcome [
         <a href="#rid42">
          42
         </a>
         ]. A clinical study using ablative fractional laser-assisted photodynamic therapy showed a high rate of recurrence and cancer incidence [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3573909302">
         <span class="h2">
          Medical and complementary therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medical therapies include retinoids,
         <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">
          vitamin A
         </a>
         , carotenoids, and NSAIDs. The rationale for using retinoids, vitamin A, and carotenoids is their putative effect on epithelial turnover. For NSAIDs, it is their modulating effect on specific prostaglandins possibly involved in carcinogenesis, while chemotherapeutic agents may act directly on early neoplastic cells.
        </p>
        <p>
         A 2016 systematic review of 14 randomized trials (909 participants) evaluated the efficacy of medical and complementary therapies, including
         <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">
          vitamin A
         </a>
         , carotenoids, retinoids, NSAIDs (
         <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">
          ketorolac
         </a>
         and
         <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">
          celecoxib
         </a>
         ), and chemotherapeutic agents [
         <a href="#rid33">
          33
         </a>
         ]. The authors concluded that none of these treatments was more effective than placebo in reducing the risk of oral SCC, although some of them, namely systemic vitamin A, beta carotene, and lycopene, were more effective than placebo in inducing the clinical resolution of the lesions [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2998053602">
         <span class="h2">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to the management of patients presenting with leukoplakia is as follows  (
         <a class="graphic graphic_algorithm graphicRef143431" href="/z/d/graphic/143431.html" rel="external">
          algorithm 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The decision about treatment approach should be discussed with the patient. The patient should be informed about the scopes, methods, risks, and possible alternatives. Regardless of the treatment choice, all patients should be educated about the importance of avoiding exposure to known risk factors for oral cancer, such as the use of tobacco (smoked and smokeless) and alcohol. In addition, regardless of the treatment approach, the patient must agree on a surveillance program aimed to make an early diagnosis in case of cancer onset.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Following histologic assessment of the lesion through multiple biopsy sampling (see
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Biopsy and histopathology'
         </a>
         above), we suggest surgical removal for leukoplakia of small sizes (up to 3 cm in the major axis), particularly when they are clinically nonhomogeneous, located in high-risk areas (eg, lateral/ventral border of the tongue, floor of the mouth), or show dysplasia on biopsy. We perform surgery with cold blade or diode laser, depending on the size of the lesion and the surgeon's preference.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who undergo surgical excision are followed up at regular intervals. We typically see patients every three months in the first year after surgery and once a year thereafter. Recurrent lesions or new lesions noted at follow-up visits should be biopsied for histopathologic evaluation. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leukoplakias that cannot be completely removed surgically because of their large size (&gt;3 cm in largest diameter), multifocality, or the patient's preference, as well as lesions that show no or mild epithelial dysplasia on biopsy, may be managed with conservative approaches, including cessation of risk habits (eg, tobacco and alcohol use) and clinical and histologic surveillance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We do not use any chemopreventive agent to treat patients with oral leukoplakia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We see patients at intervals of 3 to 12 months, depending on the clinical characteristics of the lesion and the patient's assessed risk of oral cancer (eg, current heavy smokers, alcohol drinkers). (See
         <a class="local">
          'Clinical features associated with increased risk of oral cancer'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At each follow-up visit, lesions showing clinical changes suggesting cancer (ie, increased heterogeneity, occurrence of erythematous or ulcerated areas, hardening of involved mucosa, lymphadenopathy) must be biopsied.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3656476715">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H3497973343">
         <span class="h2">
          Local recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Local recurrence or development of oral squamous cell carcinoma (SCC) occurs despite surgical removal of leukoplakia. Local recurrence or new lesions have been reported in 2 to 57 percent of patients undergoing scalpel excision, laser therapy, or cryosurgery, with 0 to 20 percent of patients developing an invasive oral SCC [
         <a href="#rid30">
          30
         </a>
         ]. In a prospective study of 103 patients with oral leukoplakia who underwent surgical excision of the entire lesion, recurrence was noted in 42 percent; the cumulative incidence of recurrence was 49 percent after five years [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1114713758">
         <span class="h2">
          Malignant transformation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Leukoplakia is a benign and asymptomatic condition. However, some patients will eventually develop SCC, even among those with lesions showing only "benign hyperkeratosis" without dysplasia on histology. The rate of cancer incidence among patients affected by oral leukoplakia is unknown. Data are limited and range from &lt;1 to 36 percent across studies [
         <a href="#rid15">
          15,45
         </a>
         ]. In a retrospective cohort of 170 patients with oral leukoplakia followed up for 12 to 219 months (median 54), malignant transformation occurred in 23 percent of patients, with an annual transformation rate of 4.9 percent [
         <a href="#rid46">
          46
         </a>
         ]. Mathematical models using worldwide data on prevalence of leukoplakia and incidence of oral cancer range have estimated an upper limit of annual transformation of &lt;1 percent [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2671523101">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regular lifetime monitoring for recurrence or further suspicious mucosal changes is recommended. We typically see patients every three months in the first year after surgery  (
         <a class="graphic graphic_algorithm graphicRef143431" href="/z/d/graphic/143431.html" rel="external">
          algorithm 2
         </a>
         ). In the absence of recurrences or development of new mucosal lesions, patients can be seen once per year thereafter. Recurrent lesions or new lesions noted at follow-up visits should be biopsied for histopathologic evaluation.
        </p>
        <p class="headingAnchor" id="H3782431165">
         <span class="h1">
          PROLIFERATIVE VERRUCOUS LEUKOPLAKIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Proliferative verrucous leukoplakia (PVL) is a rare, aggressive form of nonhomogeneous oral leukoplakia characterized by verrucous appearance, multifocality, slow growth, and high rate of malignant transformation [
         <a href="#rid48">
          48-50
         </a>
         ]. A systematic review of 20 studies including over 300 patients found a rate of transformation into oral squamous cell carcinoma (SCC) of approximately 64 percent over an average follow-up period of seven years [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         It occurs in all ethnic groups and appears to be more frequent in older women. The cause is unknown, and there is no clear association with tobacco or alcohol use or human papillomavirus (HPV) infection [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         PVL initially presents as a single or multiple leukoplakic area located on the gingiva, oral mucosa, or tongue. Over time, lesions tend to become diffuse and develop exophytic, wart-like, or erythroplakic areas, which may transform into SCC  (
         <a class="graphic graphic_picture graphicRef95480" href="/z/d/graphic/95480.html" rel="external">
          picture 4
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3955118887">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of PVL is based upon combined clinical and histopathologic features. The diagnosis is particularly difficult in the early stages of disease because lesions may mimic clinically and histologically conventional leukoplakia or oral lichen planus [
         <a href="#rid51">
          51
         </a>
         ]. Clinical clues to the diagnosis of PVL include multifocal lesions or a single, large lesion (&gt;4 cm involving one site or &gt;3 cm involving contiguous sites), presence of verrucous areas, lesions recurring after treatment, female sex, and lack of exposure to tobacco [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         Early pathologic features that may suggest PVL include a dense, lichenoid, chronic inflammation (basal vacuolar degeneration, apoptotic cells, eosinophilic bodies, and a band-like lymphocytic infiltrate); wavy (corrugated) hyperorthokeratosis; and exophytic, warty configuration  (
         <a class="graphic graphic_picture graphicRef95484" href="/z/d/graphic/95484.html" rel="external">
          picture 5
         </a>
         ).
        </p>
        <p>
         Proposed diagnostic criteria for PVL include [
         <a href="#rid53">
          53
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         White keratotic lesions that may be smooth, fissured, verrucous, or erythematous with or without ulceration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multifocal, noncontiguous lesions or a single, large lesion &gt;4 cm involving one site or a single large lesion &gt;3 cm involving contiguous sites.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lesions that progress or expand in size and/or develop multifocality over time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Histopathology that, if not overtly exhibiting dysplasia or carcinoma, shows hyperkeratosis, parakeratosis, atrophy, or acanthosis with minimal or no cytologic atypia, or verrucous hyperplasia, with or without a band-like lymphocytic infiltrate; these features must not support a diagnosis of frictional or reactive keratosis. (See
         <a class="medical medical_review" href="/z/d/html/5572.html" rel="external">
          "Oral lesions", section on 'Morsicatio buccarum and frictional keratosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1348144483">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no curative treatment for PVL. Multiple therapies have been tried for temporary control of the disease, including surgical excision, carbon dioxide (CO
         <sub>
          2
         </sub>
         ) and neodymium-doped yttrium aluminum garnet (Nd:YAG) laser ablation, cryotherapy, radiation therapy, photodynamic therapy, topical
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         , and oral retinoids. Nevertheless, more than 70 percent of patients experience recurrence and/or progression to carcinoma despite interventions [
         <a href="#rid54">
          54,55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3649307772">
         <span class="h2">
          Prognosis and follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with PVL require lifelong close clinical and histopathologic monitoring for the development of SCC [
         <a href="#rid53">
          53
         </a>
         ]. As for classic leukoplakia, patients with PVL should undergo regular follow-up at intervals of 3 to 12 months. Lesions that show suspicious changes, such as increased heterogeneity, ulcerated areas, hardening of involved mucosa, and lymphadenopathy, should be biopsied for histopathologic examination. The mortality rate after an average follow-up time of 10 years is approximately 30 percent [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4159782075">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/128559.html" rel="external">
          "Society guideline links: Head and neck cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4175046771">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and risk factors
         </strong>
         – Oral leukoplakia is an oral potentially malignant disorder that presents as white patches of the oral mucosa. It is relatively common, with a prevalence rate of approximately 4 percent. Risk factors for oral leukoplakia are similar to those for squamous cell carcinoma (SCC), including tobacco use (smoked and especially smokeless) and alcohol drinking. (See
         <a class="local">
          'Epidemiology and risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Oral leukoplakia is clinically classified in two forms, homogeneous  (
         <a class="graphic graphic_picture graphicRef81049 graphicRef72711" href="/z/d/graphic/81049.html" rel="external">
          picture 2A-B
         </a>
         ) and nonhomogeneous  (
         <a class="graphic graphic_picture graphicRef60939" href="/z/d/graphic/60939.html" rel="external">
          picture 3
         </a>
         ), with the latter carrying a higher risk of oral cancer. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above and
         <a class="local">
          'Clinical features associated with increased risk of oral cancer'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of leukoplakia requires a biopsy for histopathologic examination. Pathologic features of leukoplakia include hyperkeratosis, parakeratosis, atrophy, and inflammation, with or without dysplasia. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis includes a wide range of benign and premalignant conditions presenting as white patches or plaques of the oral mucosa  (
         <a class="graphic graphic_algorithm graphicRef118579" href="/z/d/graphic/118579.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – All patients should be counseled regarding tobacco and alcohol cessation. The management is based on the lesion size and type, histopathologic findings, and patient's assessed risk for oral cancer  (
         <a class="graphic graphic_algorithm graphicRef143431" href="/z/d/graphic/143431.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with small (&lt;3 cm) leukoplakias that have any of the following risk factors, we suggest surgical excision (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Nonhomogeneous appearance
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Location in a high-risk area (lateral/ventral border of the tongue, floor of the mouth)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Dysplasia
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with small (&lt;3 cm) leukoplakias lacking any of the above risk factors, surveillance is appropriate.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with large or multifocal leukoplakias that are not amenable to surgical removal should be offered clinical and histologic surveillance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up
         </strong>
         – As local recurrence or development of oral SCCs occur despite surgical removal of leukoplakia, lifelong close clinical follow-up every 3 to 12 months and histologic examination of all recurrent or new lesions are recommended following treatment. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Proliferative verrucous leukoplakia
         </strong>
         – Proliferative verrucous leukoplakia (PVL) is a rare, aggressive form of nonhomogeneous oral leukoplakia characterized by verrucous appearance, multifocality, slow growth, and high rate of malignant transformation  (
         <a class="graphic graphic_picture graphicRef95480" href="/z/d/graphic/95480.html" rel="external">
          picture 4
         </a>
         ). Surgical excision, laser ablation, radiation therapy, topical
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         , and oral retinoids have been tried for temporary control of PVL. However, recurrence and/or progression to carcinoma occur in more than 70 percent of patients, with a mortality rate of approximately 30 percent at 10 years. (See
         <a class="local">
          'Proliferative verrucous leukoplakia'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, et al. Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis 2021; 27:1862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mello FW, Miguel AFP, Dutra KL, et al. Prevalence of oral potentially malignant disorders: A systematic review and meta-analysis. J Oral Pathol Med 2018; 47:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang C, Li B, Zeng X, et al. The global prevalence of oral leukoplakia: a systematic review and meta-analysis from 1996 to 2022. BMC Oral Health 2023; 23:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grady D, Greene J, Daniels TE, et al. Oral mucosal lesions found in smokeless tobacco users. J Am Dent Assoc 1990; 121:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Syrjänen S, Lodi G, von Bültzingslöwen I, et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis 2011; 17 Suppl 1:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jäwert F, Fehr A, Öhman J, et al. Recurrent copy number alterations involving EGFR, CDKN2A, and CCND1 in oral premalignant lesions. J Oral Pathol Med 2022; 51:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guimarães LM, Diniz MG, Rogatto SR, et al. The genetic basis of oral leukoplakia and its key role in understanding oral carcinogenesis. J Oral Pathol Med 2021; 50:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumari P, Debta P, Dixit A. Oral Potentially Malignant Disorders: Etiology, Pathogenesis, and Transformation Into Oral Cancer. Front Pharmacol 2022; 13:825266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villa A, Hanna GJ, Kacew A, et al. Oral keratosis of unknown significance shares genomic overlap with oral dysplasia. Oral Dis 2019; 25:1707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonçalves AS, Mosconi C, Jaeger F, et al. Overexpression of immunomodulatory mediators in oral precancerous lesions. Hum Immunol 2017; 78:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ries J, Agaimy A, Wehrhan F, et al. Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia. Biomedicines 2021; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanna GJ, Villa A, Mistry N, et al. Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. Cancer Res Commun 2021; 1:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robledo-Sierra J, Ben-Amy DP, Varoni E, et al. World Workshop on Oral Medicine VII: Targeting the oral microbiome Part 2: Current knowledge on malignant and potentially malignant oral disorders. Oral Dis 2019; 25 Suppl 1:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogelstein B, Kinzler KW. The Path to Cancer --Three Strikes and You're Out. N Engl J Med 2015; 373:1895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arduino PG, Bagan J, El-Naggar AK, Carrozzo M. Urban legends series: oral leukoplakia. Oral Dis 2013; 19:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siebers TJ, Bergshoeff VE, Otte-Höller I, et al. Chromosome instability predicts the progression of premalignant oral lesions. Oral Oncol 2013; 49:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brito JA, Gomes CC, Guimarães AL, et al. Relationship between microRNA expression levels and histopathological features of dysplasia in oral leukoplakia. J Oral Pathol Med 2014; 43:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angiero F, Berenzi A, Benetti A, et al. Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity. Anticancer Res 2008; 28:2535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monteiro L, Mello FW, Warnakulasuriya S. Tissue biomarkers for predicting the risk of oral cancer in patients diagnosed with oral leukoplakia: A systematic review. Oral Dis 2021; 27:1977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Waal I. Oral leukoplakia, the ongoing discussion on definition and terminology. Med Oral Patol Oral Cir Bucal 2015; 20:e685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Waal I. Oral potentially malignant disorders: is malignant transformation predictable and preventable? Med Oral Patol Oral Cir Bucal 2014; 19:e386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Speight PM, Khurram SA, Kujan O. Oral potentially malignant disorders: risk of progression to malignancy. Oral Surg Oral Med Oral Pathol Oral Radiol 2018; 125:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brouns E, Baart J, Karagozoglu Kh, et al. Malignant transformation of oral leukoplakia in a well-defined cohort of 144 patients. Oral Dis 2014; 20:e19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Napier SS, Cowan CG, Gregg TA, et al. Potentially malignant oral lesions in Northern Ireland: size (extent) matters. Oral Dis 2003; 9:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 2008; 37:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kujan O, Khattab A, Oliver RJ, et al. Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: an attempt to understand the sources of variation. Oral Oncol 2007; 43:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villa A, Woo SB. Leukoplakia-A Diagnostic and Management Algorithm. J Oral Maxillofac Surg 2017; 75:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farah CS, Woo SB, Zain RB, et al. Oral cancer and oral potentially malignant disorders. Int J Dent 2014; 2014:853479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranganathan K, Kavitha L, Sharada P, et al. Intra-observer and inter-observer variability in two grading systems for oral epithelial dysplasia: A multi-centre study in India. J Oral Pathol Med 2020; 49:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerr AR, Lodi G. Management of oral potentially malignant disorders. Oral Dis 2021; 27:2008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmstrup P, Dabelsteen E. Oral leukoplakia-to treat or not to treat. Oral Dis 2016; 22:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Oral premalignant lesions: is a biopsy reliable? J Oral Pathol Med 2007; 36:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodi G, Franchini R, Warnakulasuriya S, et al. Interventions for treating oral leukoplakia to prevent oral cancer. Cochrane Database Syst Rev 2016; 7:CD001829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monteiro L, Barbieri C, Warnakulasuriya S, et al. Type of surgical treatment and recurrence of oral leukoplakia: A retrospective clinical study. Med Oral Patol Oral Cir Bucal 2017; 22:e520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jerjes W, Upile T, Hamdoon Z, et al. CO2 laser of oral dysplasia: clinicopathological features of recurrence and malignant transformation. Lasers Med Sci 2012; 27:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuribayashi Y, Tsushima F, Sato M, et al. Recurrence patterns of oral leukoplakia after curative surgical resection: important factors that predict the risk of recurrence and malignancy. J Oral Pathol Med 2012; 41:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang SW, Tsai CN, Lee YS, Chen TA. Treatment outcome of dysplastic oral leukoplakia with carbon dioxide laser--emphasis on the factors affecting recurrence. J Oral Maxillofac Surg 2011; 69:e78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mogedas-Vegara A, Hueto-Madrid JA, Chimenos-Küstner E, Bescós-Atín C. The treatment of oral leukoplakia with the CO2 laser: A retrospective study of 65 patients. J Craniomaxillofac Surg 2015; 43:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arduino PG, Lodi G, Cabras M, et al. A Randomized Controlled Trial on Efficacy of Surgical Excision of Nondysplastic Leukoplakia to Prevent Oral Cancer. Cancer Prev Res (Phila) 2021; 14:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Hem PS, Nauta JM, van der Wal JE, Roodenburg JL. The results of CO2 laser surgery in patients with oral leukoplakia: a 25 year follow up. Oral Oncol 2005; 41:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez-Lujan A, López-Jornet P, Pons-Fuster López E. Recurrence of Oral Leukoplakia after CO2 Laser Resection: A Prospective Longitudinal Study. Cancers (Basel) 2022; 14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Y, Wang B, Zheng S, He Y. Photodynamic therapy in the treatment of oral leukoplakia: A systematic review. Photodiagnosis Photodyn Ther 2019; 25:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yao YL, Wang YF, Li CX, et al. Management of oral leukoplakia by ablative fractional laser-assisted photodynamic therapy: A 3-year retrospective study of 48 patients. Lasers Surg Med 2022; 54:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundberg J, Korytowska M, Holmberg E, et al. Recurrence rates after surgical removal of oral leukoplakia-A prospective longitudinal multi-centre study. PLoS One 2019; 14:e0225682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson A, Ishak N. Marked variation in malignant transformation rates of oral leukoplakia. Evid Based Dent 2015; 16:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evren I, Brouns ER, Wils LJ, et al. Annual malignant transformation rate of oral leukoplakia remains consistent: A long-term follow-up study. Oral Oncol 2020; 110:105014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheifele C, Reichart PA. Is there a natural limit of the transformation rate of oral leukoplakia? Oral Oncol 2003; 39:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillenwater AM, Vigneswaran N, Fatani H, et al. Proliferative verrucous leukoplakia (PVL): a review of an elusive pathologic entity! Adv Anat Pathol 2013; 20:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagan J, Scully C, Jimenez Y, Martorell M. Proliferative verrucous leukoplakia: a concise update. Oral Dis 2010; 16:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pentenero M, Meleti M, Vescovi P, Gandolfo S. Oral proliferative verrucous leucoplakia: are there particular features for such an ambiguous entity? A systematic review. Br J Dermatol 2014; 170:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson LDR, Fitzpatrick SG, Müller S, et al. Proliferative Verrucous Leukoplakia: An Expert Consensus Guideline for Standardized Assessment and Reporting. Head Neck Pathol 2021; 15:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Issrani R, Prabhu N, Keluskar V. Oral proliferative verrucous leukoplakia: A case report with an update. Contemp Clin Dent 2013; 4:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villa A, Menon RS, Kerr AR, et al. Proliferative leukoplakia: Proposed new clinical diagnostic criteria. Oral Dis 2018; 24:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abadie WM, Partington EJ, Fowler CB, Schmalbach CE. Optimal Management of Proliferative Verrucous Leukoplakia: A Systematic Review of the Literature. Otolaryngol Head Neck Surg 2015; 153:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Proaño-Haro A, Bagan L, Bagan JV. Recurrences following treatment of proliferative verrucous leukoplakia: A systematic review and meta-analysis. J Oral Pathol Med 2021; 50:820.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 118618 Version 5.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33128420" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29738071" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prevalence of oral potentially malignant disorders: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37670255" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The global prevalence of oral leukoplakia: a systematic review and meta-analysis from 1996 to 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2370378" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Oral mucosal lesions found in smokeless tobacco users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21382139" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35488777" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Recurrent copy number alterations involving EGFR, CDKN2A, and CCND1 in oral premalignant lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33217066" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The genetic basis of oral leukoplakia and its key role in understanding oral carcinogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35517828" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Oral Potentially Malignant Disorders: Etiology, Pathogenesis, and Transformation Into Oral Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31295753" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Oral keratosis of unknown significance shares genomic overlap with oral dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28941745" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Overexpression of immunomodulatory mediators in oral precancerous lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33669300" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36860910" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31140694" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : World Workshop on Oral Medicine VII: Targeting the oral microbiome Part 2: Current knowledge on malignant and potentially malignant oral disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26559569" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The Path to Cancer --Three Strikes and You're Out.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23379968" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Urban legends series: oral leukoplakia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24075955" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Chromosome instability predicts the progression of premalignant oral lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24020903" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Relationship between microRNA expression levels and histopathological features of dysplasia in oral leukoplakia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19035275" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33290585" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Tissue biomarkers for predicting the risk of oral cancer in patients diagnosed with oral leukoplakia: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26449439" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Oral leukoplakia, the ongoing discussion on definition and terminology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24905952" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Oral potentially malignant disorders: is malignant transformation predictable and preventable?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29396319" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Oral potentially malignant disorders: risk of progression to malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23521625" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Malignant transformation of oral leukoplakia in a well-defined cohort of 144 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12945594" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Potentially malignant oral lesions in Northern Ireland: size (extent) matters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18251935" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16931119" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: an attempt to understand the sources of variation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27865803" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Leukoplakia-A Diagnostic and Management Algorithm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24891850" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Oral cancer and oral potentially malignant disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32516857" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Intra-observer and inter-observer variability in two grading systems for oral epithelial dysplasia: A multi-centre study in India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34324758" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Management of oral potentially malignant disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26785709" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Oral leukoplakia-to treat or not to treat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17448135" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Oral premalignant lesions: is a biopsy reliable?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27471845" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Interventions for treating oral leukoplakia to prevent oral cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28809365" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Type of surgical treatment and recurrence of oral leukoplakia: A retrospective clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21494890" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : CO2 laser of oral dysplasia: clinicopathological features of recurrence and malignant transformation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22697318" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Recurrence patterns of oral leukoplakia after curative surgical resection: important factors that predict the risk of recurrence and malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21398012" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Treatment outcome of dysplastic oral leukoplakia with carbon dioxide laser--emphasis on the factors affecting recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25913630" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The treatment of oral leukoplakia with the CO2 laser: A retrospective study of 65 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32958584" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A Randomized Controlled Trial on Efficacy of Surgical Excision of Nondysplastic Leukoplakia to Prevent Oral Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15598583" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The results of CO2 laser surgery in patients with oral leukoplakia: a 25 year follow up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36358873" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Recurrence of Oral Leukoplakia after CO2 Laser Resection: A Prospective Longitudinal Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30391342" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Photodynamic therapy in the treatment of oral leukoplakia: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35253237" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Management of oral leukoplakia by ablative fractional laser-assisted photodynamic therapy: A 3-year retrospective study of 48 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31810078" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Recurrence rates after surgical removal of oral leukoplakia-A prospective longitudinal multi-centre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26680515" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Marked variation in malignant transformation rates of oral leukoplakia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33038723" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Annual malignant transformation rate of oral leukoplakia remains consistent: A long-term follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12747971" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Is there a natural limit of the transformation rate of oral leukoplakia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24113312" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Proliferative verrucous leukoplakia (PVL): a review of an elusive pathologic entity!
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20233330" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Proliferative verrucous leukoplakia: a concise update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24471527" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Oral proliferative verrucous leucoplakia: are there particular features for such an ambiguous entity? A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33415517" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Proliferative Verrucous Leukoplakia: An Expert Consensus Guideline for Standardized Assessment and Reporting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24015023" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Oral proliferative verrucous leukoplakia: A case report with an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29337414" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Proliferative leukoplakia: Proposed new clinical diagnostic criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26044786" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Optimal Management of Proliferative Verrucous Leukoplakia: A Systematic Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33765364" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Recurrences following treatment of proliferative verrucous leukoplakia: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
